Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 10, 2014, Pages 791-804

  Pacifico, L ^a   Giansanti, S ^a   Gallozzi, A ^a   Chiesa, C ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Children; Docosapentaenoic acid; Eicosapentaenoic acid; Long chain omega 3 fatty acids; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FISH OIL; G PROTEIN COUPLED RECEPTOR 120; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INSULIN RECEPTOR SUBSTRATE 1; LEUKOTRIENE C4; LINOLENIC ACID; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THROMBOXANE A2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED CLINICAL TRIAL (TOPIC); DIAPEDESIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DYSLIPIDEMIA; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADOLESCENT; ANALYSIS; CHILD; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADOLESCENT; CHILD; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84911458923     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Mozumdar, A.; Liguori, G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care, 2011, 34, 216-219.
2. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 356-359.
3. Meigs, J.B.; Wilson, P.W.; Nathan, D.M.; D'Agostino, R.B. Sr.; Williams, K.; Haffner, S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 2003, 52, 2160-2167.
4. Al-Sarraj, T.; Saadi, H.; Volek, J.S.; Fernandez, M.L. Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profile among overweight and obese adults 18-50 years old from the United Arab Emirates. Metab. Syndr. Relat. Disord., 2010, 8, 39-46.
5. Barquera, S.; Campos-Nonato, I.; Aguilar-Salinas, C.; Lopez- Ridaura, R.; Arredondo, A.; Rivera-Dommarco, J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health, 2013, 9, 3.
6. Steinberger, J.; Daniels, S.R.; Eckel, R.H.; Hayman, L.; Lustig, R.H.; McCrindle, B.; Mietus-Snyder, M.L.; American heart association atherosclerosis, hypertension, and obesity in the young committee of the council on cardiovascular disease in the young; council on cardiovascular nursing; and council on nutrition, physical activity, and metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the american heart association atherosclerosis, hypertension, and obesity in the young committee of the council on cardiovascular disease in the young; council on cardiovascular nursing; and council on nutrition, physical activity, and metabolism. Circulation, 2009, 119, 628-647.
7. Cook, S.; Weitzman, M.; Auinger, P.; Nguyen, M.; Dietz, W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med., 2003, 157, 821-827.
8. Johnson, W.D.; Kroon, J.J.; Greenway, F.L.; Bouchard, C.; Ryan, D.; Katzmarzyk, P.T. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. Arch. Pediatr. Adolesc. Med., 2009, 163, 371-377.
9. Zimmet, P.; Alberti, K.G.; Kaufmann, F.; Tajima, N.; Silink, M.; Arslanian, S.; Wong, G.; Bennett, P.; Shaw, J.; Caprio, S.; IDF Consensus Group. The metabolic syndrome in children and adolescents: An IDF consensus report. Pediatr. Diabetes, 2007, 8, 299-306.
10. Grundy, S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab., 2007, 92, 399-404.
11. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. The metabolic syndrome. Endocr. Rev., 2008, 29, 777-822.
12. Kotronen, A.; Yki-Järvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 27-38.
13. Pacifico, L; Anania, C.; Martino, F.; Cantisani, V.; Pascone, R.; Marcantonio, A.; Chiesa, C. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1643-1651.
14. Pacifico, L.; Di Martino, M.; De Merulis, A.; Bezzi, M.; Osborn, J.F.; Catalano, C.; Chiesa, C. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology, 2014, 59, 461-470.
15. Pacifico, L.; Nobili, V.; Anania, C.; Verdecchia, P.; Chiesa, C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J. Gastroenterol., 2011, 17, 3082-3091.
16. Pacifico, L.; Chiesa, C.; Anania, C.; De Merulis, A.; Osborn, J.F.; Romaggioli, S.; Gaudio, E. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J. Gastroenterol., 2014, 20, 9055-9071.
17. Pacifico, L.; Poggiogalle, E.; Cantisani, V.; Menichini, G.; Ricci, P.; Ferraro, F.; Chiesa, C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J. Hepatol., 2010, 2, 275-288.
18. Mencin, A.A.; Lavine, J.E. Advances in pediatric nonalcoholic fatty liver disease. Pediatr. Clin. North. Am., 2011, 58, 1375-1392.
19. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
20. Andersen, C.J.; Fernandez, M.L. Dietary strategies to reduce metabolic syndrome. Rev. Endocr. Metab. Disord., 2013, 14, 241-254.
21. Yamaoka, K.; Tango, T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med., 2012, 10, 138.
22. Feldeisen, S.E.; Tucker, K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl. Physiol. Nutr. Metab., 2007, 32, 46-60.
23. Pacifico, L.; Anania, C.; Martino, F.; Poggiogalle, E.; Chiarelli, F.; Arca, M.; Chiesa, C. Management of metabolic syndrome in children and adolescents. Nutr. Metab. Cardiovasc. Dis., 2011, 21, 455-466.
24. International Union of Pure and Applied Chemistry. Commission on the Nomenclature of Organic Chemistry. Nomenclature of organic chemistry, 4th ed.; Pergamon Press, Oxford, New York, 1979, 1-537, Rigaudy, J.; Klesney, S.P.(eds).
25. IUPAC-IUB Commission on Biochemical Nomenclature (CBN). The nomenclature of lipids. Eur. J. Biochem., 1977, 79, 11-21.
26. De Filippis, A.P.; Sperling, L.S. Understanding omega-3’s. Am. Heart J., 2006, 151, 564-570.
27. Burdge, G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7, 137-144.
28. Sprecher, H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim. Biophys. Acta, 2000, 1486, 219-231.
29. Wang, Y.; Botolin, D.; Christian, B.; Busik, J.; Xu, J.; Jump, D.B. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J. Lipid Res., 2005, 46, 706-715.
30. Igarashi, M.; DeMar, J.C.; Ma, K.; Chang, L.; Bell, J.M.; Rapoport, S.I. Docosahexaenoic acid synthesis from a-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J. Lipid Res., 2007, 48, 1150-1158.
31. Kim, K.B.; Nam, Y.A.; Kim, H.S.; Hayes, A.W.; Lee, B.M. αLinolenic acid: nutraceutical, pharmacological and toxicological evaluation. Food Chem. Toxicol., 2014, 70C, 163-178.
32. Cordain, L.; Eaton, S.B.; Sebastian, A.; Mann, N.; Lindeberg, S.; Watkins, B.A.; O'Keefe, J.H.; Brand-Miller, J. Origins and evolution of the Western diet: health implications for the 21st century. Am. J. Clin. Nutr., 2005, 81, 341-354.
33. Scorletti, E.; Byrne, C.D. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev. Nutr., 2013, 33, 231-248.
34. Lorente-Cebrián, S.; Costa, A.G.; Navas-Carretero, S.; Zabala, M.; Martínez, J.A.; MorenoAliaga, M.J. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: A review of the evidence. J. Physiol. Biochem., 2013, 69, 633-651.
35. Schmitz, G.; Ecker, J. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res., 2008, 47, 147-155.
36. Calder, P.C. Omega-3 fatty acids and inflammatory processes. Nutrients, 2010, 2, 355-374.
37. Serhan, C.N.; Arita, M.; Hong, S.; Gotlinger, K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids, 2004, 39, 1125-1132.
38. Calder, P.C., Yaqoob, P. Understanding omega-3 polyunsaturated fatty acids. Postgrad. Med., 2009, 121, 148-157.
39. Trumbo, P.; Schlicker, S.; Yates, A.A.; Poos, M.; Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J. Am. Diet Assoc., 2002, 102, 1621-1630.
40. Gebauer, S.K.; Psota, T.L.; Harris, W.S.; Kris-Etherton, P.M. n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am. J. Clin. Nutr., 2006, 83 (Suppl. 6), S1526-S1535.
41. American Heart Association Nutrition Committee.; Lichtenstein, A.H.; Appel, L.J.; Brands, M.; Carnethon, M.; Daniels, S.; Franch, H.A.; Franklin, B.; Kris-Etherton P.; Harris, W.S.; Howard, B.; Karanja, N.; Lefevre, M.; Rudel, L.; Sacks, F.; Van Horn, L.; Winston, M.; Wylie-Rosett, J. Diet and Lifestyle Recommendations Revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation, 2006, 114, 82-96.
42. Lee, J.H. Polyunsaturated fatty acids in children. Pediatr. Gastroenterol. Hepatol. Nutr., 2013, 16, 153-161.
43. Obesity and overweight. World Health Organisation [online], 2011.
44. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444, 840-846.
45. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
46. Das, U.N. Is obesity an inflammatory condition? Nutrition, 2001, 17, 953-966.
47. Buckley, J.D.; Howe, P.R. Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity-a review. Nutrients, 2010, 2, 1212-1230.
48. Martinez-Victoria, E.; Yago, M.D. Omega-3 polyunsaturated fatty acids and body weight. Br. J. Nutr., 2012, 107 (Suppl. 2), S107-S116.
49. Kabir, M.; Skurnik, G.; Naour, N.; Pechtner, V.; Meugnier, E.; Rome, S.; Quignard- Boulangé, A.; Vidal, H.; Slama, G.; Clément, K.; Guerre-Millo, M.; Rizkalla, S.W. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr., 2007, 86, 1670-1679.
50. Munro, I.A.; Garg, M.L. Prior supplementation with long chain omega-3 polyunsaturated fatty acids promotes weight loss in obese adults: a double-blinded randomised controlled trial. Food Funct., 2013, 4, 650-658.
51. Munro I.A.; Garg, M.L. Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very- lowenergy diet. Br. J. Nutr., 2012, 108, 1466-1474.
52. Crochemore, I.C.; Souza, A.F.; de Souza, A.C.; Rosado, E.L. Omega-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutr. Clin. Pract., 2012, 27, 553-560.
53. Bender, N.; Portmann, M.; Heg, Z.; Hofmann, K.; Zwahlen M.; Egger M. Fish or n3-PUFA intake and body composition:a systematic review and meta-analysis. Obes. Rev., 2014, 15, 657-665.
54. Kennedy, K.; Ross, S.; Isaacs, E.B.; Weaver, L.T.; Singhal, A.; Lucas, A.; Fewtrell, M.S. The 10-year follow-up of a randomised trial of long-chain polyunsaturated fatty acid supplementation in preterm infants: effects on growth and blood pressure. Arch. Dis. Child., 2010, 95, 588-595.
55. Nobili, V.; Bedogni, G.; Alisi, A.; Pietrobattista, A.; Risé, P.; Galli, C.; Agostoni, C. Docosahexaenoic acid supplementation decreases liver fat content in children with nonalcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch. Dis. Child., 2011, 96, 350-353.
56. López-Alarcón, M.; Martínez-Coronado, A.; Velarde-Castro, O.; Rendón-Macías, E.; Fernández, J. Supplementation of n3 longchain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children. Arch. Med. Res., 2011, 42, 502-508.
57. Vasickova, L.; Stavek, P.; Suchanek, P. Possible effect of DHA intake on body weight reduction and lipid metabolism in obese children. Neuro Endocrinol. Lett., 2011, 32 (Suppl. 2), S64-S67.
58. Nobili, V.; Alisi, A.; Della Corte, C.; Risé, P.; Galli, C.; Agostoni, C.; Bedogni, G. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr. Metab. Cardiovasc. Dis., 2013, 23, 1066-1070.
59. Juárez-López, C.; Klünder-Klünder, M.; Madrigal-Azcárate, A.; Flores-Huerta, S. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatr. Diabetes., 2013, 14, 377-383.
60. De Ferranti, S.D.; Milliren, C.E.; Denhoff, E.R.; Steltz, S.K.; Selamet Tierney, E.S.; Feldman, H.A.; Osganian, S.K. Using highdose omega-3 fatty acid supplements to lower triglyceride levels in 10-to 19-year-olds. Clin. Pediatr. (Phila), 2014, 53, 428-438.
61. Ukropec, J.; Reseland, J.E.; Gasperikova, D.; Demcakova, E.; Madsen, L.; Berge, R.K.; Rustan, A.C.; Klimes, I.; Drevon, C.A.; Sebökova, E. The hypotriglyceridemic effect of dietary n-3 FA is associated with increased beta-oxidation and reduced leptin expression. Lipids, 2003, 38, 1023-1029.
62. Couet, C.; Delarue, J.; Ritz, P.; Antoine, J.M.; Lamisse, F. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int. J. Obes. Relat. Metab. Disord., 1997, 21, 637-643.
63. Baltzell, J.K.; Wooten, J.T.; Otto, D.A. Lipoprotein lipase in rats fed fish oil: apparent relationship to plasma insulin levels. Lipids, 1991, 26, 289-294.
64. Rashid, S.; Watanabe, T.; Sakaue, T.; Lewis, G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin. Biochem., 2003, 36, 421-429.
65. Lopez-Alvarenga, J.C.; Ebbesson, S.O.; Ebbesson, L.O.; Tejero, M.E.; Voruganti, V.S.; Commuzzie, A.G. Polyunsaturated fatty acids effect on serum triglycerides concentration in the presence of metabolic syndrome components. The Alaska-Siberia Project. Metabolism, 2010, 59, 86-92.
66. Nestel, P.; Shige, H.; Pomeroy, S.; Cehun, M.; Abbey, M.; Raederstorff, D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am. J. Clin. Nutr., 2002, 76, 326-330.
67. Harris, W.S. N-3 fatty acids and serum lipoproteins: Human studies. Am. J. Clin. Nutr., 1997, 65 (Suppl. 5), S1645-S1654.
68. Friedberg, C.E.; Janssen, M.J.; Heine, R.J.; Grobbee, D.E. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care, 1998, 21, 494-500.
69. Bernstein, A.M.; Ding, E.L.; Willett, W.C.; Rimm, E.B. A metaanalysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDLcholesterol and LDLcholesterol in persons without coronary heart disease. J. Nutr., 2012, 142, 99-104.
70. Micallef, M.A.; Garg, M.L. The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women. J. Nutr., 2008, 138, 1086-1090.
71. Mori, T.A.; Bao, D.Q.; Burke, V.; Puddey, I.B.; Watts, G.F.; Beilin, L.J. Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am. J. Clin. Nutr., 1999, 70, 817-825.
72. Hartweg, J.; Perera, R.; Montori, V.; Dinneen, S.; Neil, H.A.; Farmer, A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2008, CD003205.
73. Kelley, D.S.; Siegel, D.; Vemuri, M.; Mackey, B.E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am. J. Clin. Nutr., 2007, 86, 324-333.
74. Jacobson, T.A. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr., 2008, 87 (Suppl. 6), S1981-S1990.
75. Kelley, D.S.; Adkins, Y. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc. Nutr. Soc., 2012, 71, 322-331.
76. Grimsgaard, S.; Bonaa, K.H.; Hansen, J.B.; Nordøy, A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr., 1997, 66, 649-659.
77. Mori, T.A.; Burke, V.; Puddey, I.B.; Watts, G.F.; O'Neal, D.N.; Best, J.D.; Beilin, L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr., 2000, 71, 1085-1094.
78. Rambjør, G.S.; Wålen, A.I.; Windsor, S.L.; Harris, W.S. Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids, 1996, 31, S45-S49.
79. Hansen, J.B.; Grimsgaard, S.; Nilsen, H.; Nordøy, A.; Bønaa, K.H. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia. Lipids, 1998, 33, 131-138.
80. Cottin, S.C.; Sanders, T.A.; Hall, W.L. The differential effects of EPA and DHA on cardiovascular risk factors. Proc. Nutr. Soc., 2011, 70, 215-231.
81. Suzukawa, M.; Abbey, M.; Howe, P.R.; Nestel, P.J. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J. Lipid Res., 1995, 36, 473-484.
82. Calabresi, L.; Donati, D.; Pazzucconi, F.; Sirtori, C.R.; Franceschini, G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis, 2000, 148, 387-396.
83. Thomas, T.R.; Smith, B.K.; Donahue, O.M.; Altena, T.S.; James-Kracke, M.; Sun, G.Y. Effects of omega-3 fatty acid supplementation and exercise on low-density lipoprotein and high-density lipoprotein subfractions. Metabolism, 2004, 53, 749-754.
84. Griffin, M.D.; Sanders, T.A.; Davies, I.G.; Morgan, L.M.; Millward, D.J.; Lewis, F.; Slaughter, S.; Cooper, J.A.; Miller, G.J.; Griffin, B.A. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. Am. J. Clin. Nutr., 2006, 84, 1290-1298.
85. Mostad, I.L.; Bjerve, K.S.; Lydersen, S.; Grill, V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur. J. Clin. Nutr., 2008, 62, 419-429.
86. Egert, S.; Kannenberg, F.; Somoza, V.; Erbersdobler, H.F.; Wahrburg, U. Dietary alphalinolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J. Nutr., 2009, 139, 861-868.
87. Woodman, R.J.; Mori, T.A.; Burke, V.; Puddey, I.B.; Watts, G.F.; Best, J.D.; Beilin, L.J. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care, 2003, 26, 253.
88. Theobald, H.E.; Chowienczyk, P.J.; Whittall, R.; Humphries, S.E.; Sanders, T.A. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am. J. Clin. Nutr., 2004, 79, 558-563.
89. Engler, M.M.; Engler, M.B.; Malloy, M.J.; Paul, S.M.; Kulkarni, K.R.; Mietus-Snyder, M.L. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am. J. Cardiol., 2005, 95, 869-871.
90. Neff, L.M.; Culiner, J.; Cunningham-Rundles, S.; Seidman, C.; Meehan, D.; Maturi, J.; Wittkowski, K.M.; Levine, B.; Breslow, J.L. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J. Nutr., 2011, 141, 207-213.
91. Buckley, R.; Shewring, B.; Turner, R.; Yaqoob, P.; Minihane, A.M. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br. J. Nutr., 2004, 92, 477-483.
92. Damsgaard, C.T.; Schack-Nielsen, L.; Michaelsen, K.F.; Fruekilde, M.B.; Hels, O.; Lauritzen, L. Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants. J. Nutr., 2006, 136, 94-99.
93. Pedersen, M.H.; Mølgaard, C.; Hellgren, L.I.; Lauritzen, L. Effects of fish oil supplementation on markers of the metabolic syndrome. J. Pediatr., 2010, 157, 395-400.
94. Verduci, E.; Agostoni, C.; Radaelli, G.; Banderali, G.; Riva, E.; Giovannini, M. Blood lipids profile in hyperlipidemic children undergoing different dietary long chain polyunsaturated supplementations: a preliminary clinical trial. Int. J. Food Sci. Nutr., 2014, 65, 375-379.
95. Chan, D.C.; Watts, G.F.; Mori, T.A.; Barrett, P.H.; Redgrave, T.G.; Beilin, L.J. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am. J. Clin. Nutr., 2003, 77, 300-307.
96. Pan, M.; Maitin, V.; Parathath, S.; Andreo, U.; Lin, S.X.; St Germain, C.; Yao, Z.; Maxfield, F.R.; Williams, K.J.; Fisher, E.A. Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 5862-5867.
97. Caviglia, J.M.; Gayet, C.; Ota, T.; Hernandez-Ono, A.; Conlon, D.M.; Jiang, H.; Fisher, E.A.; Ginsberg, H.N. Different fatty acids inhibit apoB100 secretion by different pathways: Unique roles for ER stress, ceramide, and autophagy. J. Lipid Res., 2011, 52, 1636-1651.
98. Olivieri, O.; Martinelli, N.; Sandri, M.; Bassi, A.; Guarini, P.; Trabetti, E.; Pizzolo, F.; Girelli, D.; Friso, S.; Pignatti, P.F.; Corrocher, R. Apolipoprotein C-III, n-3 polyunsaturated fatty acid, and “insulin-resistant” T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin. Chem., 2005, 51, 360-367.
99. Ingelfinger, J.R. Clinical practice. The child or adolescent with elevated blood pressure. N. Engl. J. Med., 2014, 370, 2316-2325.
100. Campbell, F.; Dickinson, H.O.; Critchley, J.A.; Ford, G.A.; Bradburn, M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur. J. Prev. Cardiol., 2013, 20, 107-120.
101. Miller, P.E.; Van Elswyk, M.; Alexander, D.D. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am. J. Hypertens., 2014, 27, 885-896.
102. Mozaffarian, D. Fish, n-3 fatty acids, and cardiovascular haemodynamics. J. Cardiovasc. Med. (Hagerstown), 2007, 8 (Suppl. 1), S23-S26.
103. Wang, Q.; Liang, X.; Wang, L.; Lu, X.; Huang, J.; Cao, J.; Li, H.; Gu, D. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis, 2012, 221, 536-543.
104. Egert, S.; Stehle, P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr. Opin. Clin. Nutr. Metab. Care, 2011, 14, 121-131.
105. Forsyth, J.S.; Willatts, P.; Agostoni, C.; Bissenden, J.; Casaer, P.; Boehm, G. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: Follow up of a randomized controlled trial. BMJ, 2003, 326, 953.
106. Skilton, M.R.; Raitakari, O.T.; Celermajer, D.S. High intake of dietary long-chain ω-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008. Hypertension, 2013, 61, 972-976.
107. Ayer, J.G.; Harmer, J.A.; Xuan, W.; Toelle, B.; Webb, K.; Almqvist, C.; Marks, G.B.; Celermajer, D.S. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: Effects on blood pressure and arterial structure and function at age 8 y. Am. J. Clin. Nutr., 2009, 90, 438-446.
108. Francois, H.; Coffman, T.M. Prostanoids and blood pressure: which way is up? J. Clin. Invest., 2004, 114, 757-759.
109. Kinsella, J.E.; Lokesh, B.; Stone, R.A. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am. J. Clin. Nutr., 1990, 52, 1-28.
110. Hoshi, T.; Wissuwa, B.; Tian, Y.; Tajima, N.; Xu, R.; Bauer, M.; Heinemann, S.H.; Hou, S. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca²⁺dependent K⁺ channels. Proc. Natl. Acad. Sci. USA, 2013, 110, 4816-4821.
111. Sinha, R.; Fisch, G.; Teague, B.; Tamborlane, W.V.; Banyas, B.; Allen, K.; Savoye, M.; Rieger, V.; Taksali, S.; Barbetta, G.; Sherwin, R.S.; Caprio, S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N. Engl. J. Med., 2002, 346, 802-810.
112. Tsitouras, P.D.; Gucciardo, F.; Salbe, A.D.; Heward, C.; Harman, S.M. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm. Metab. Res., 2008, 40, 199-205.
113. Esposito, K.; Marfella, R.; Ciotola, M.; Di Palo, C.; Giugliano, F.; Giugliano, G.; D'Armiento, M.; D'Andrea, F.; Giugliano, D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA, 2004, 292, 1440-1446.
114. Giacco, R.; Cuomo, V.; Vessby, B.; Uusitupa, M.; Hermansen, K.; Meyer, B.J.; Riccardi, G.; Rivellese, A.A.; KANWU Study Group. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr. Metab. Cardiovasc. Dis., 2007, 17, 572-580.
115. Woodman, R.J.; Mori, T.A.; Burke, V.; Puddey, I.B.; Watts, G.F.; Beilin, L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am. J. Clin. Nutr., 2002, 76, 1007-1015.
116. Dangardt, F.; Chen, Y.; Gronowitz, E.; Dahlgren, J.; Friberg, P.; Strandvik, B. High physiological omega-3 Fatty Acid supplementation affects muscle fatty acid composition and glucose and insulin homeostasis in obese adolescents. J. Nutr. Metab., 2012, 2012, Article ID 395757.
117. Burrows, T.; Collins, C.E.; Garg, M.L. Omega-3 index, obesity and insulin resistance in children. Int. J. Pediatr. Obes., 2011, 6, e532-e539.
118. Oliver, E.; McGillicuddy, F.; Phillips, C.; Toomey, S.; Roche, H.M. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. Proc. Nutr. Soc., 2010, 69, 232-243.
119. Day, C.P.; James, O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology, 1998, 114, 842-845.
120. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.
121. Cortez-Pinto, H.; Jesus, L.; Barros, H.; Lopes, C.; Moura, M.C.; Camilo, M.E. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr., 2006, 25, 816-823.
122. Vilar, L.; Oliveira, C.P.M.S.; Faintuch, J.; Mello, E.S.; Nogueira, M.A.; Santos, T.E.; Alves, V.A.; Carrilho, F.J. High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects. Nutrition, 2008, 24, 1097-1102.
123. Zelber-Sagi, S.; Nitzan-Kaluski, D.; Goldsmith, R.; Webb, M.; Blendis, L.; Halpern, Z.; Oren, R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J. Hepatol., 2007, 47, 711-717.
124. Parker, H.M.; Johnson, N.A.; Burdon, C.A.; Cohn, J.S.; O'Connor, H.T.; George, J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol., 2012, 56, 944-951.
125. Pettinelli, P.; del Pozo, T.; Araya, J.; Rodrigo, R.; Araya, A.V.; Smok, G.; Csendes, A.; Gutierrez, L.; Rojas, J.; Korn, O.; Maluenda, F.; Diaz, J.C.; Rencoret, G.; Braghetto, I.; Castillo, J.; Poniachik, J.; Videla, L.A. Enhancement in liver SREBP1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim. Biophys. Acta, 2009, 1792, 1080-1086.
126. Araya, J.; Rodrigo, R.; Videla, L.A.; Thielemann, L.; Orellana, M.; Pettinelli, P.; Poniachik, J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci., 2004, 106, 635-643.
127. Elizondo, A.; Araya, J.; Rodrigo, R.; Poniachik, J.; Csendes, A.; Maluenda, F.; Díaz, J.C.; Signorini, C.; Sgherri, C.; Comporti, M.; Videla, L.A. Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity, 2007, 15, 24-31.
128. Sekiya, M.; Yahagi, N.; Matsuzaka, T.; Najima, Y.; Nakakuki, M.; Nagai, R.; Ishibashi, S.; Osuga, J.; Yamada, N.; Shimano, H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology, 2003, 38, 1529-1539.
129. Capanni, M.; Calella, F.; Biagini, M.R.; Genise, S.; Raimondi, L.; Bedogni, G.; Svegliati-Baroni, G.; Sofi, F.; Milani, S.; Abbate, R.; Surrenti, C.; Casini, A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non- alcoholic fatty liver disease: A pilot study. Aliment. Pharmacol. Ther., 2006, 23, 1143-1151.
130. Cussons, A.J.; Watts, G.F.; Mori, T.A.; Stuckey, B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J. Clin. Endocrinol. Metab., 2009, 94, 3842-3848.
131. Spadaro, L.; Magliocco, O.; Spampinato, D.; Piro, S.; Oliveri, C.; Alagona, C.; Papa, G.; Rabuazzo, A.M.; Purrello, F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver. Dis., 2008, 40, 194-199.
132. Vega, G.L.; Chandalia, M.; Szczepaniak, L.S.; Grundy, S.M. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J. Investig. Med., 2008, 56, 780-785.
133. Hatzitolios, A.; Savopoulos, C.; Lazaraki, G.; Sidiropoulos, I.; Haritanti, P.; Lefkopoulos, A.; Karagiannopoulou, G.; Tzioufa, V.; Dimitrios, K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J. Gastroenterol., 2004, 23, 131-134.
134. Tanaka, N.; Sano, K.; Horiuchi, A.; Tanaka, E.; Kiyosawa, K.; Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol., 2008, 42, 413-418.
135. Zhu, F.S.; Liu, S.; Chen, X.M.; Huang, Z.G.; Zhang, D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol., 2008, 14, 6395-6400.
136. Sofi, F.; Giangrandi, I.; Cesari, F.; Corsani, I.; Abbate, R.; Gensini, G.F.; Casini, A. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non- alcoholic fatty liver disease patients: a preliminary study. Int. J. Food Sci. Nutr., 2010, 61, 792-802.
137. Scorletti, E.; Bhatia, L.; McCormick, K.G.; Clough, G.F.; Nash, K.; Hodson, L.; Moyses, H.E.; Calder, P.C.; Byrne, C.D.; On behalf of the WELCOME Study Investigators. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME study. Hepatology, 2014, Jul 4 [Epub ahead of print]
138. Dasarathy, S.; Dasarathy, J.; Khiyami, A.; Yerian, L.; Hawkins, C.; Sargent, R.; McCullough, A.J. Double-blind Randomized Placebo- controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. J. Clin. Gastroenterol., 2014, Feb 27 [Epub ahead of print]
139. Nobili, V.; Carpino, G.; Alisi, A.; De Vito, R.; Franchitto, A.; Alpini, G.; Onori, P.; Gaudio, E. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One, 2014, 9, e88005.
140. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell, 2010, 142, 687-698.
141. Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; Choquet, H.; Besnard, P.; Lecoeur, C.; Vivequin, S.; Ayukawa, K.; Takeuchi, M.; Ozawa, K.; Tauber, M.; Maffeis, C.; Morandi, A.; Buzzetti, R.; Elliott, P.; Pouta, A.; Jarvelin, M.R.; Körner, A.; Kiess, W.; Pigeyre, M.; Caiazzo, R.; Van Hul, W.; Van Gaal, L.; Horber, F.; Balkau, B.; Lévy-Marchal, C.; Rouskas, K.; Kouvatsi, A.; Hebebrand, J.; Hinney, A.; Scherag, A.; Pattou, F.; Meyre, D.; Koshimizu, T.A.; Wolowczuk, I.; Tsujimoto, G.; Froguel, P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature, 2012, 483, 350-354.
142. Talukdar, S.; Olefsky, J.M.; Osborn, O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci., 2011, 32, 543-550.
143. Janczyk, W.; Socha, P.; Lebensztejn, D.; Wierzbicka, A.; Mazur, A.; Neuhoff-Murawska, J.; Matusik, P. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr., 2013, 13, 85.
144. Jump, D.B. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipidol., 2008, 19, 242-247.
145. Marx, N.; Duez, H.; Fruchart, J.C.; Staels, B. Peroxisome proliferator- activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res., 2004, 94, 1168-1178.
146. Pawar, A.; Jump, D.B. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J. Biol. Chem., 2003, 278, 35931-35939.
147. Nagasawa, T.; Inada, Y.; Nakano, S.; Tamura, T.; Takahashi, T.; Maruyama, K.; Yamazaki, Y.; Kuroda, J.; Shibata, N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline- deficient diet. Eur. J. Pharmacol., 2006, 536, 182-191.
148. Brown, J.D.; Plutzky, J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation, 2007, 115, 518-533.
149. Stienstra, R.; Mandard, S.; Patsouris, D.; Maass, C.; Kersten, S.; Müller, M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology, 2007, 148, 2753-2763.
150. Tetri, L.H.; Basaranoglu, M.; Brunt, E.M.; Yerian, L.M.; Neuschwander-Tetri, B.A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a highfructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 295, G987-G995.
151. Botolin, D.; Wang, Y.; Christian, B.; Jump, D.B. Docosahexaneoic acid (22: 6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erkand 26S proteasome-dependent pathways. J. Lipid. Res., 2006, 47, 181-192.
152. Yahagi, N.; Shimano, H.; Hasty, A.H.; Amemiya-Kudo, M.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Shionoiri, F.; Ohashi, K.; Osuga, J.; Harada, K.; Gotoda, T.; Nagai, R.; Ishibashi, S.; Yamada, N. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem., 1999, 274, 35840-35844.
153. Xu, J.; Nakamura, M.T.; Cho, H.P.; Clarke, S.D. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem., 1999, 274, 23577-23583.
154. Worgall, T.S.; Sturley, S.L.; Seo, T.; Osborne, T.F.; Deckelbaum, R.J. Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein. J. Biol. Chem., 1998, 273, 25537-25540.
155. Kim, H.J.; Takahashi, M.; Ezaki, O. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J. Biol. Chem., 1999, 274, 25892-25898.
156. Dentin, R.; Benhamed, F.; Pégorier, J.P.; Foufelle, F.; Viollet, B.; Vaulont, S.; Girard, J.; Postic, C. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J. Clin. Invest., 2005, 115, 2843-2854.